Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanofi Pasteur versus Lanzhou meningococcal A+C polysaccharide vaccine in children aged 2 to 6 years in China
2015-005189-48Phase 4
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Meningococcal (groups A and C) polysaccharide vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Seroconversion after vaccination and Non-inferiority of seroconversion rate for serogroups A and C.
02
Drugs
Meningococcal (groups A and C) polysaccharide vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2015-005189-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005189-48.